Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZD334 phase IIb study in high-risk patients with stable coronary artery disease
2020-000942-32Phase 2Terminated
- Sponsor
- Inflazome
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of selnoflast in coronary arteriosclerosis (3 arms), sponsored by Inflazome. Primary endpoint: Mean change in CRP at 12 weeks of 450 mg IZD334 compared to placebo. Started Jun 2020; status: terminated.
02
Drugs
selnoflast
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2020-000942-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000942-32.